2015 中山大学-墨尔本皇家理工大学联合研讨会通知

2015 中山大学-墨尔本皇家理工大学联合研讨会通知

(2015 SYSU-RMIT Joint Symposium)

 

    2015 中山大学-墨尔本皇家理工大学联合研讨会将在我院举行。本次研讨会是我院与墨尔本皇家理工大学签署合作备忘录后，首次举办的联合学术会议，研讨内容涉及药学研究多个领域，届时提供会议茶歇，欢迎感兴趣的老师和同学踊跃参加！

 

时间：2015年11月17日上午9:00-12:00

地点：bm11222宝马娱乐网站125讲学厅

 

报告一

时  间：11月17日上午9:25-9:45

题  目：Targeting novel oxidant-dependent mechanisms to treat acute and chronic lung diseases

报告人：Prof. Ross Vlahos, Principal Research Fellow

Head of the Respiratory Research Group

School of Health Sciences, RMIT University

 

报告人简介：

Associate Professor Ross Vlahos is a Principal Research Fellow and Head of the Respiratory Research Group in the School of Health Sciences, RMIT University.  His research aims to identify novel strategies for the prevention and treatment of COPD and its co-morbidities with a focus on the cellular and molecular pathways that underpin cigarette smoke-induced lung inflammation and damage.  Ross has co-authored more than 70 publications in peer reviewed journals and has been successful in obtaining highly competitive research funding support from national funding bodies including NHMRC Australia, philanthropic sources, foundations, Universities and industry totalling over $7.5 million.  He has also played a major role in commercially funded work that has confidentiality/patent agreements.  Ross has served on various national (e.g. NHMRC Australia) and international (e.g. MRC UK, European Research Society) funding bodies, numerous conference committees and Chaired sessions at international meetings.  Ross is an Editorial Board member and regular reviewer for leading international journals in the field of respiratory medicine, pharmacology and immunology.  He is currently a member of the American Thoracic Society’s (peak international professional society for respiratory physicians/scientists) Assembly of Allergy, Immunology and Inflammation Program and Executive Committees and is Co-Chair of the International Relations Committee.  He is regularly invited to present his research findings at various international conferences, research institutes, hospitals and major international pharmaceutical companies.  Ross has supervised a number of Honours, Masters and PhD students to completion and is committed to supporting and encouraging young researchers in their career development.

 

 

报告二

 

时  间：11月17日上午9:45-10:05

题  目：Why does inflammation fail to resolve in chronic obstructive pulmonary disease

报告人：Prof. Steven Bozinovski, Head of the Airways Inflammation Research Group, RMIT University

 

报告人简介：

A/Prof Bozinovski is head of the Airways Inflammation Research Group at RMIT University and a current Australian Research Council (ARC) Future Fellow. His research career is identified with fundamental contributions to the field of chronic airways disease, and has had a long standing interest in understanding why inflammation in COPD is persistent and refractory to current medications. He has driven translational research efforts with clinicians at the Royal Melbourne Hospital involving the screening of cohorts in excess of 100 patients for the discovery of novel COPD exacerbation biomarkers. These projects have identified the ALX/FPR2 receptor ligand, Serum Amyloid A (SAA) as a major mediator of steroid resistant lung inflammation in COPD and his team is now investigating the counter regulatory actions of this receptor as a novel approach to controlling excessive inflammation. His team consistently publishes in internationally leading scientific and respiratory journals, and is on organizing committees for major thoracic national and international conferences (American Thoracic Society and Thoracic Society of Australia and NZ). He has have been consistently successful in obtaining highly competitive research funding support within Australia including 5x National Health & Medical Research Council (NHMRC) project grants since 2007 (4 as lead investigator) and an ARC Fellowship (2014-2017). He has supervised to completion 10x PhD, Masters and Honours students over the past decade including 2 students that received Dux of their cohort year. He is an Editorial Board member and regular reviewer for leading international journals in the field of respiratory medicine, pharmacology and immunology. He has served as an NHMRC GRP panel member (2011-2013) and currently serves on the NHMRC Assigners Academy (2014-ongoing). He currently serves as a executive member of the Lung Health research Centre, which is a University endorsed centre at the University of Melbourne.

 

 

报告三

时  间：11月17日上午10:15-10:35

题  目：Approaches of reducing ectopic lipids for the discovery of novel anti-diabetic drugs

报告人：Prof. Jiming Ye, Director of Exercise, Metabolism and Disease Program

Head of the Lipid Biology and Metabolic Disease Laboratory

Director of Postgraduate Research of the School of Health

Sciences

 

报告人简介：

Prof Jiming Ye has a research career for over 30 years after his medical training and a Master degree in China. He obtained his PhD degree in the University of Tasmania in Australia with Prof Michael Clark in vascular control of energy metabolism. He was a NHMRC Senior Research Officer with Prof Edward Kraegen at Garvan Institute (Australia) between 1997 and 2003. After one year of clinical trials in Eli Lilly, he returned to Garvan Institute in 2005 leading the research of drug discovery for diabetes and was a conjoint Assoc Prof of the University of NSW (2008-2013). In 2010, he joined RMIT University as an Assoc Prof and established the Molecular Pharmacology for Diabetes Laboratory. Since 2012, he has been a Professor for Ageing and Chronic Disease Management. Prof Ye’s research focuses on two fundamental areas in Type 2 diabetes and fatty liver disease: molecular mechanisms of these metabolic disorders and novel therapeutic approaches for the related diseases. His investigation of the molecular mechanisms focuses on the roles of fatty acid oxidation and synthesis, mitochondrial dysfunction, ER stress and autophagy in the development of insulin resistance and fatty liver disease. Based on identified targets (incl. AMPK, SIRT, FoxO1, HSP72 and epigenetic regulations), his lab conducts research in drug discovery and molecular pharmacology for type 2 diabetes and fatty liver disease. Prof Ye has published >90 peer-reviewed research papers > 4600 total citations and 4 patents. He has expertise in insulin resistant cell/animal models, tracer techniques, biochemical assays, signalling pathways and gene expression for metabolic studies. His current research interests include: 1) Nutrition compositions and metabolic disease, 2) Type 2 diabetes, lipid biology and insulin resistance, 3) Mitochondrial dysfunction, ER stress and autophagy, 4) Metabolic memory and epigenetic regulation, and 5) Drug discovery and molecular pharmacology. Currently, Prof Ye is the Director of the Metabolism, Exercise and Disease Program of 18 research groups. He also leads RMIT’s collaborations with Sun Yat-sen University, Shanghai Institute of Materia Medica and South China University of Technology.

 

报告四

时  间：11月17日上午10:35-10:55

题  目：Discovering active moieties from Chinese herbal medicine

报告人：徐峻 教授，bm11222宝马娱乐网站

 

报告人简介：

Jun Xu, PhD, Professor and Founding Director of Research Center for Drug Discovery (RCDD) at Sun Yat-Sen University (SYSU), Adjunct Professor of Pharmaceutical Sciences in the School of Pharmacy at Department of Pharmaceutical Sciences in University of Pittsburgh. Prior to joining SYSU, he worked in the pharmaceutical industry, practicing chemoinformatics and computer-aided drug design (CADD) for over 20 years. He was director of CADD at DPI/Biofocus, a drug discovery CRO, a principal scientist managing the computational chemistry and chemoinformatics group at Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). Before joining BIPI, I held an R&D director position at BIO-RAD Sadtler Division. His main focus at SYSU has been to apply the principles of chemoinformatics and CADD to medicinal chemistry and traditional Chinese medicine (TCM) remedies. His team has developed TCM databases, high performance computing (HPC) algorithms for chemical structure recognitions, classifications, drug-likeness, compound stability, 3D molecular superimposing/similarity, virtual drug screening, new technologies for natural product extractions and syntheses. His labs are equipped for natural product or traditional Chinese medicine (TCM) extraction, separation, purification, structure elucidation, biological screening, crystallography, synthetic biology, and a number of bio-assay platforms. His current research interests are HPC applications in CADD and medicinal chemistry, TCM modernization, lead discovery and optimizations for anti-cancer, anti-infectious, anti-metabolic syndrome, graph theory and machine learning algorithms for big data process.

 

 

报告五

时  间：11月17日上午10:55-11:15

题  目：Therapeutic targets and drugs for atherosclerosis

报告人：李卓明 博士，bm11222宝马娱乐网站

 

报告人简介：

Zhuoming LI, Lecturer in Pharmacology, School of Pharmaceutical Sciences, Sun Yat-sen University. Dr. Li obtained her Ph.D degree at the University of Hong Kong in 2012. In the same year, she joined SYSU and has been a lecturer in Laboratory of Pharmacology & Toxicology (in Prof. Peiqing Liu’s team) until now. Dr. Li’s major research field is cardiovascular pharmacology. Her research interests include: (1) endothelial regulation of vascular tone, in particular endothelium-dependent contractions and endothelium-dependent hyperpolarizations; (2) endothelial senescence, endothelial dysfunction and endothelial inflammation in cardiovascular diseases; (3) pathogenesis and potential therapeutic targets of vascular diseases, in particular atherosclerosis; (4) cardiovascular activity of biologically active components of Traditional Chinese Medicine and natural plants. Until recently, she has published 12 original research papers, some of which are in top journals such as Hypertension, British Journal of Pharmacology, AJP-Heart & Circulatory Physiology, etc.

 

 

报告六

时  间：11月17日上午11:15-11:35

报告题目：Design the Nanoparticles Formulation for Peptide Delivery System based on pMDIs

报告人：潘昕 博士，bm11222宝马娱乐网站

 

报告人简介：

       Xin Pan, Lecturer in Pharmaceutics, School of Pharmaceutical Sciences, Sun Yat-sen University. Dr. Pan obtained her Ph.D degree at Sun Yat-sen University in 2011. After graduation, she stayed and was employed by the school and has been a lecturer in Laboratory of Pharmaceutics. Dr. Pan’s research interests are mainly on: (1) Controlled and sustained release drug delivery system; (2) Targeted drug delivery system. Her current research projects include: (1) Granulated coated pellets technology for pellet-containing tablet ; (2) Ultra-fine particle processing system for long-acting injection microspheres; (3) Improving the FPF values based on binary carriers for dry powder inhalers; (4) Pressurized metered dose inhalation for peptide delivery. Until now she has published more than 20 research papers on peer-reviewed journals, such as Journal of Nanobiotechnology, European Journal of Pharmaceutics and Biopharmaceutics, etc.

 

 

附录：

 

研讨会议程

 

 

时间	议程
09:00-09:10	院长致欢迎辞
09:10-09:20	RMIT代表发言
09:20-09:25	吴传斌教授宣布研讨会开始
09:25-09:45	学术报告：“Targeting novel oxidant-dependent mechanisms to treat acute and chronic lung diseases" -RMIT Prof. Ross Vlahos
09:45-10:05	学术报告：“Why does inflammation fail to resolve in chronic obstructive pulmonary disease ” -RMIT Prof. Steven Bozinovski
10:05-10:15	茶歇
10:15-10:35	学术报告：“Approaches of reducing ectopic lipids for the discovery of novel anti-diabetic drugs" - RMIT Prof. Jiming
10:35-10:55	学术报告：“Discovering active moieties from Chinese herbal medicine” -中山大学徐峻教授
10:55-11:15	学术报告：“Therapeutic targets and drugs for atherosclerosis” -中山大学李卓明老师
11:15-11:35	学术报告：“Design the Nanoparticles Formulation for Peptide Delivery System based on pMDIs” -中山大学潘昕老师
11:35-11:50	交流环节（现场教师、研究生提问，交流）
11:50-12:00	研讨会总结(黄志纾教授)
12:00-12:05	研讨活动结束